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Introduction
Whether to use a medication during pregnancy can be a
concern for both women and health care providers. It has
The ﬁndings and conclusions in this report are those of the authors
and do not necessarily represent the views of the Centers for Disease
Control and Prevention.
J. D. Cragan ()
National Center on Birth Defects and Developmental Disabilities,
Centers for Disease Control and Prevention, MS E-86,
1600 Clifton Road, N.E., Atlanta, GA 30333
e-mail: jcragan@cdc.gov
J. M. Friedman
Department of Medical Genetics, University of British Columbia,
Vancouver, British Columbia, Canada
L. B. Holmes
Genetics and Teratology Unit, MassGeneral Hospital for Children,
Boston, MA
K. Uhl
Center for Drug Evaluation and Research, Food and Drug
Administration,
Silver Spring, MD
N. S. Green
March of Dimes Birth Defects Foundation,
White Plains, NY
L. Riley
Department of Obstetrics and Gynecology, Brigham and
Women’s Hospital,
Boston, MA
been estimated that up to 10% of congenital anomalies
may be caused by environmental exposures–that is, expo-
sures to medications, alcohol, or other exogenous factors
that have adverse effects on the developing embryo or fe-
tus [1]. Avoiding all potentially adverse exposures can pre-
vent these adverse effects. However, it is not always possi-
ble to avoid taking medications during pregnancy. Women
who are pregnant continue to experience short-term and
long-term health conditions that must be managed. Dis-
continuing treatment of a serious condition when a woman
becomes pregnant can have profound, long-term implica-
tions both for her health and that of her baby. In a retro-
spective study from eight health maintenance organizations,
researchers estimated that approximately 59% of pregnant
women were prescribed a medication other than a vitamin
or mineral supplement at some time during pregnancy [2].
Use of over-the-counter medications during pregnancy may
be even higher, and many women take a dietary or herbal
supplement other than multivitamins or folic acid while
pregnant [3, 4].
Preconception care provides the opportunity to optimize
a woman’s use of medications in preparation for pregnancy.
Such care includes identifying patterns of medication use
before pregnancy occurs; adjusting those patterns to avoid
the use of nonessential medications; minimizing exposure
to medications known to be harmful to the embryo or fetus;
and adjusting the dose, route of administration, and tim-
ing of essential treatments to optimize maternal health at
each stage of pregnancy while safeguarding the embryo,
fetus, and infant. In this paper, we summarize the basic
principles of teratology and the current state of knowl-
edge about the effects of medication use during pregnancy;
outline basic components of preconception care that can
help minimize the risk of birth defects; and provide exam-
ples of approaches to planning for the safe and effective
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use of medications during pregnancy through preconception
care.
Principles of teratology
The term “teratogen” is sometimes used to describe an agent
that can produce structural or functional abnormalities in a
developing embryo or fetus. Although this implies that an
agent is inherently either teratogenic or not, teratogenicity
is actually a property of the exposure taken as whole—
not only the physical and chemical nature of the agent,
but also the dose, route of administration, and timing in
gestation, as well as concurrent exposure to other agents
and biological susceptibility of the mother and embryo or
fetus.
The developmental stage of the embryo or fetus at the
time of exposure is critical. During conception and for about
2 weeks thereafter, most cells of the conceptus are not yet
committed to a speciﬁc developmental program. One dam-
aged cell can be replaced by another, and normal devel-
opment will usually ensue, although the embryo will not
survive if too many cells are damaged or killed. This is
known as the “all-or-nothing” period, but even during this
period some exposures can adversely affect the develop-
ment of surviving embryos [5]. The subsequent period of
organogenesis, from 18 to 60 days after conception (about
4.5–11 weeks after the start of the last normal menstrual
period) is the time of greatest sensitivity to most terato-
genic exposures. Fetal exposure later in gestation usually
does not produce gross structural abnormalities, although
there are exceptions. Adverse exposures during the fetal pe-
riod more often result in growth restriction or functional
disorders of the central nervous system, kidneys, or other
organs.
Dose is a critical feature of any teratogenic exposure.
Teratogenic effects occur only when the dose of an agent
exceeds a certain threshold [1]. Medications that are gen-
erally considered safe during pregnancy can have adverse
effects on the embryo or fetus if the mother takes them
in doses that are so high that they cause maternal toxicity.
Chronic exposure is usually of more concern than a sin-
gle exposure, if the doses are similar. The route of expo-
sure is also important. For example, risk is unlikely from
the use of dermal agents that lack substantial systemic ab-
sorption. The teratogenicity of an exposure is also inﬂu-
enced by both the maternal and fetal genotypes, which can
result in differences in cell sensitivity, placental transport,
metabolism, receptor binding, or drug distribution. Some
medicationsaremetabolizedextensivelybythemother;their
teratogenicitydependsuponwhetheratoxicformreachesthe
embryo or fetus in sufﬁcient quantities to produce adverse
effects.
Current state of knowledge about the effects
of medication use during pregnancy
Maternal effects
Many women begin pregnancy with medical conditions that
require ongoing or episodic treatment. Examples include
asthma, epilepsy, and hypertension. In addition, other med-
ical problems, such as migraine headache or auto-immune
disorders,maybeexacerbatedbypregnancy.Whenplanning
for the management of maternal conditions during preg-
nancy, it is important to distinguish conditions for which
withholding treatment could be harmful to the mother, em-
bryo, or fetus, from those for which cessation of treatment is
unlikely to pose signiﬁcant risk. For example, women with
majordepressionwhodiscontinueantidepressantmedication
before conception are at high risk of relapse and consequent
self-injurious or even suicidal behavior [6]. In contrast, ces-
sationoftreatmentformoderatehypercholesterolemiawitha
statin drug while a woman is pregnant is unlikely to increase
her cardiovascular morbidity or mortality signiﬁcantly.
Physiologicchangesoccurduringpregnancythatcanalter
the effective dose of medications a woman is taking. Some
changes occur abruptly, while others evolve slowly. Most
begin during the ﬁrst trimester and peak during the second
trimester of pregnancy [7]. It may be necessary to adjust the
dose and/or frequency of medication use repeatedly during
pregnancy. Physiologic changes that can affect the pharma-
cokinetics and/or pharmacodynamics of medications during
pregnancy include:
– Changes in total body weight and body fat composition.
– Delayedgastricemptying,prolongedgastrointestinaltran-
sit time, and decreased gastric acid secretion, all of which
can affect the bioavailability of drugs [8–10].
– Expanded plasma volume and signiﬁcantly increased ex-
tracellular ﬂuid space and total body water content. These
vary with the patient’s weight and can affect the volume
of distribution of drugs [11].
– Increased cardiac output, stroke volume, heart rate, and
blood ﬂow to the uterus, kidneys, skin, and mammary
glands.Thepercentageofcardiacoutputattributedtohep-
atic blood ﬂow is lower during pregnancy [12].
– Decreased concentration of plasma albumin, which can
reduce the protein binding of some drugs [13].
– Increased glomerular ﬁltration rate early in pregnancy,
with a continued rise throughout pregnancy [14].
– Changes in the activity of hepatic enzymes, including
the cytochrome P450 enzymes, xanthine oxidase, and N-
acetyltransferase [15, 16].
Unfortunately, there are relatively few studies of
drug pharmacokinetics during pregnancy. The dose of
medicationsusuallyprescribedduringpregnancyisthesame
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used in nonpregnant adults, but this may result in substan-
tial under- or over-dosage during pregnancy. When blood or
serum concentrations of medications can be measured and
the most effective level is known, they should be monitored
throughout pregnancy and appropriate dosage adjustments
made as needed. Further well-designed and well-conducted
pharmacokinetic and pharmacodynamic studies of medica-
tions during pregnancy are needed.
Fetal effects
Maternal treatment with conventional doses of some med-
ications during a susceptible period of pregnancy is known
to be harmful to the developing embryo. Thalidomide and
isotretinoin are the most notable examples, but there are
others [17]. In contrast, taking some other medications
or dietary supplements such as folic acid helps to prevent
adverse pregnancy outcomes [18]. Because pregnant women
are traditionally excluded from clinical trials for ethical
reasons and because premarketing animal studies do not
necessarily predict the effects of treatment in human preg-
nancy, little information about the teratogenic risks or safety
of most drugs is available at the time they are marketed.
Animal teratology studies are not routinely conducted for
non-prescription drugs, vitamins, and dietary and herbal
supplements, although these substances may produce
pharmacological or toxic effects in the fetus. Moreover,
there is no standard requirement for studies of adverse
effects among children of women who took a drug during
pregnancyafterithasbeenapprovedbytheFDA.Inareview
conducted in 2001, researchers found that there was not
enough information to assess the teratogenic risk or safety
during human pregnancy of more than 90% of prescription
medications approved by the FDA in the previous 20 years
[19].
Even when available, studies addressing fetal effects of
maternalmedicationuseduringpregnancymayprovidecon-
ﬂicting results or insufﬁcient information to assess all poten-
tial outcomes or levels of risk. The concept of safety implies
the absence of risk, which is impossible to demonstrate con-
clusively with any kind of study. Thus, it can be difﬁcult for
women and health care providers to decide whether to use
a medication during pregnancy. The balance of risk, beneﬁt,
and efﬁcacy of treatment for both mother and fetus is not
always clear and must be individualized for different women
under different circumstances.
Basic components of preconception care that can
minimize the risk of birth defects
Seriouscongenitalanomalies,includingchromosomeabnor-
malities and Mendelian disorders, can be identiﬁed in about
2% of infants at birth [52]. However, some anomalies do not
become apparent until later in life [20]. While most birth
defects are not preventable, some can be avoided through
appropriate planning and medical interventions. The follow-
ingcomponentsofpreconceptioncarecanhelpminimizethe
risk of birth defects:
– Optimize health before conception occurs. This includes
counseling women to avoid smoking, use of excessive
alcohol and illicit drugs, and exposure to potentially toxic
environmental or occupational hazards before they are
pregnant.
– Establisheffectivetreatmentforchronicconditionsbefore
conception occurs.
– Carefully manage all chronic conditions and intercurrent
illnesses throughout pregnancy.
– Counsel women to avoid the use of nonessential medica-
tions, including prescription and over-the-counter medi-
cations and dietary or herbal supplements.
– Avoid the use of medications with high teratogenic risk
when equally effective treatments with lower risks are
available.
– Limittheuseofessentialmedicationstothesmallestnum-
ber of drugs possible that will effectively treat maternal
disease without compromising the health of the woman or
her fetus.
– Limit each essential medication to the smallest dose that
can be used to effectively treat maternal disease without
compromising the health of the woman or her fetus.
– Recommend that all women who are capable of becoming
pregnant take a vitamin supplement or eat fortiﬁed foods
toassureconsumptionof0.4mg(400micrograms)offolic
acid per day.
Effective pregnancy management in women with chronic
conditions requires careful planning, close medical supervi-
sion before and during pregnancy, and continuous commu-
nication between the pregnant woman and her health care
providers.
Examples of approaches to preconception planning
for the use of medications during pregnancy
in different clinical settings
Exactly how the components of preconception planning for
the use of medications during pregnancy are implemented
depends on the nature of the condition requiring treatment,
the known risks and safety of use of the speciﬁc drugs dur-
ing pregnancy, and the woman’s individual circumstances,
among other factors. In this section, we provide three exam-
ples of approaches to planning for the safe and effective use
of medications in clinical settings where these factors vary.
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Avoiding teratogenic treatments for non life-threatening
maternal conditions—isotretinoin
Isotretinoin is indicated for the treatment of severe nodular
cystic acne unresponsive to other therapy but is also used
to treat non-nodular, but scarring, acne. A single course
of therapy typically lasts 15–20 weeks and can result in
complete and prolonged remission of the acne in many pa-
tients. However, isotretinoin treatment in the ﬁrst trimester
of pregnancy is teratogenic. Exposed infants can have cran-
iofacial, cardiac, thymic, and central nervous system mal-
formations [21]. Research has also shown a high incidence
of developmental delay in children whose mothers used
isotretinoin early in the ﬁrst trimester, regardless of whether
the children had structural malformations [22].
Isotretinoin is indicated for use only in men and non-
pregnant women. It should never be used during pregnancy.
However, because approximately half of pregnancies in the
United States are unintended, some women use isotretinoin
in the early weeks of gestation before realizing they are
pregnant [23]. Teratogenic outcomes have been reported
after only one dose of isotretinoin during pregnancy [24].
The half-life of isotretinoin is approximately 24 h, but about
2 weeks are required to eliminate 99% of the drug from the
body after cessation of use.
Several risk management strategies have been imple-
mented to prevent the use of isotretinoin during pregnancy,
but pregnancy exposures continue to occur [25]. An en-
hanced risk management program called iPLEDGE became
fully operational in March 2006 [26, 27]. iPLEDGE is a sin-
gle, mandatory program for all marketed isotretinoin prod-
ucts. It requires that wholesalers, pharmacies, doctors, and
patients register with the program in order to obtain the
drug. Female patients who are capable of having children
must obtain counseling about the risks of isotretinoin treat-
ment and the requirements for its safe use; complete an
informed consent form; have two negative pregnancy tests
documentedbeforestartingisotretinointherapy;usetwodif-
ferent forms of contraception simultaneously or agree not
to engage in heterosexual intercourse for one month prior
to starting isotretinoin, throughout the course of treatment,
and for one month after completing treatment; and have a
negative pregnancy test documented every month during
treatment and one month after completing treatment. More
information about the iPLEDGE program can be found at
www.ipledgeprogram.com.
Preconception care provides a unique and critical oppor-
tunity to prevent exposure to teratogens such as isotretinoin.
Any woman who is considering pregnancy should be asked
whether she is taking any medications including any prepa-
ration containing isotretinoin. If so, her health care provider
should emphasize the risks of isotretinoin use during preg-
nancy, reevaluate the need for and duration of treatment,
assess thoroughly the use and effectiveness of contraceptive
measures, and reinforce the key elements of the iPLEDGE
program. Women should be informed that conception can-
not be attempted without risk of teratogenicity until one full
month after the last dose of isotretinoin was taken. Educa-
tional information and materials from the iPLEDGE pro-
gram can also be helpful in the setting of preconception
care.
Managing maternal conditions that require continuous
treatment—epilepsy
At least one in every 250 pregnant women, or about 0.4%,
takes an anticonvulsant drug [28]. Approximately half take
the drugs to prevent seizures, but anticonvulsants are also
used to manage mood disorders, migraine headaches, and
chronic pain. Anticonvulsant drugs have several different
modes of action, such as targeting a speciﬁc receptor or en-
zyme [29]. As a result, anticonvulsant medications vary in
their effectiveness for speciﬁc types of epilepsy. Individuals
with epilepsy may respond differently to particular medica-
tions, reﬂecting genetic differences such as polymorphisms
in the cytochrome P450 enzymes. It is not yet possible to
screen for pharmacogenetic differences that would help se-
lect the appropriate anticonvulsant for individual use. Physi-
ologic changes during pregnancy also can affect the disposi-
tion of anticonvulsant drugs and the dose needed to prevent
seizures [30].
While not all anticonvulsant drugs have been studied in
pregnancy, a number of adverse effects have been identiﬁed
in infants and children of women treated with these med-
ications during pregnancy. Major malformations, midface
and digit hypoplasia, microcephaly, growth restriction, and
deﬁcits in IQ are sometimes seen, although the pattern of
abnormalities and speciﬁc effects vary for individual drugs
[28, 31–33]. For example, spina biﬁda occurs in approxi-
mately 1% of fetuses exposed to carbamazepine and in 2
to 5% of fetuses exposed to valproic acid [34, 35]; micro-
cephaly and growth restriction are observed more frequently
in infants whose mothers took two or more anticonvulsant
drugs simultaneously during pregnancy [28]; and subtle ef-
fects on intelligence have been identiﬁed in some studies of
children exposed to carbamazepine, phenytoin, or phenobar-
bital in utero, although developmental delay and deﬁcits in
cognitive function are much more frequent with exposure
to valproic acid [36–38]. While some infants exposed to an
anticonvulsant drug in utero have abnormalities, others do
not. Genetic differences in the fetal response to medications
probably play a role.
It has been hypothesized that maternal epilepsy might
cause fetal abnormalities independent of any drug effect,
but several studies suggest that anticonvulsant treatments
are usually responsible [39]. However, it seems likely that
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repeated or prolonged maternal seizures, such as occur in
status epilepticus, can be devastating to the fetus [40]. Dis-
continuation or inadequate treatment of maternal epilepsy
may be more dangerous to the fetus than effective anticon-
vulsant therapy.
Preconception care provides an opportunity to choose a
plan of anticonvulsant treatment that will pose the least risk
to the fetus while appropriately managing maternal symp-
toms. New data about the effects on the fetus of anticonvul-
sant medications are emerging steadily, and the latest infor-
mation should always be sought. The treatment plan must
be individualized for each woman in collaboration with her
neurologist, psychiatrist, or other specialist. Primary consid-
erations include assessing whether taking an anticonvulsant
drug is essential to the mother’s health; using the fewest
number of anticonvulsant drugs possible; using the low-
est dose for each drug that will effectively treat maternal
symptoms [41]; establishing the most effective blood level
of each drug before conception; and monitoring drug lev-
els throughout pregnancy. For carbamazepine, phenobarbi-
tal, phenytoin, primidone, and valproic acid, levels of the
non-protein bound, or “free,” concentration should be mea-
sured. Because abrupt cessation of a medication may result
in increased seizures or exacerbation of other symptoms, the
number and dose of medications should be adjusted, and the
woman’s response stabilized, over a period of time before
attempting conception.
In addition, preconception care offers the opportunity to
consider whether additional measures, such as the use of a
higher daily dose of folic acid, might be beneﬁcial. Only
limited and somewhat conﬂicting information is available
about whether periconceptional supplementation with folic
acid at levels higher than 0.4 mg per day decreases the risk
for neural tube defects associated with anticonvulsant drug
exposure in utero [33, 42]. Currently, many women who
require anticonvulsant drug therapy during pregnancy take 4
or 5 mg of folic acid daily.
Managing maternal conditions with intermittent
symptoms—asthma
Asthma is a chronic condition with intermittent symptoms,
for which treatment during pregnancy is essential to safe-
guard the health and well-being of both the mother and fe-
tus. Abrupt cessation or undertreatment of asthma during
pregnancy can endanger both. Studies suggest that maternal
asthma during pregnancy can increase the risk for perina-
tal mortality, preeclampsia, preterm delivery, and low birth
weight [43, 44]. Maternal asthma can lead to alkalosis with
decreased blood ﬂow to the uterus, decreased venous return,
andaleftwardshiftoftheoxyhemoglobindissociationcurve,
all of which may contribute to fetal hypoxia. In the extreme,
maternal hypoxia can result in decreased umbilical blood
ﬂow, increased systemic and pulmonary vascular resistance
in the fetus, and decreased fetal cardiac output. Fetal com-
promise may occur well before maternal symptoms become
severe [45]. Additional pathophysiologic mechanisms that
could contribute to these adverse outcomes include hyperac-
tivityofuterineandbronchialsmoothmuscleandtherelease
of bioactive mediators during symptomatic asthma [43]. For
thesereasons,itisconsideredsaferforpregnantwomentobe
treated with asthma medications than to experience asthma
symptoms and exacerbations [46].
A variety of medications are available to treat acute and
chronic asthma. They include beta2-agonoists, corticos-
teroids, cromolyn, leukotriene modiﬁers, theophylline, and
anticholinergics. These drugs have different mechanisms
of action and thus potentially different effects on the fetus.
Before attempting conception, it is important to maximize
asthma control using medications that can also be used
to manage asthma symptoms during pregnancy. This will
ensure maximum oxygen delivery to the developing embryo
and fetus while avoiding unintended medication exposures.
A period of time may be needed to wean patients off some
medications and to stabilize symptoms using others before
attempting conception. In addition, because an estimated
one third of pregnant women with asthma experience an
increase in the frequency or severity of their symptoms
during pregnancy, it is important to develop a plan before
conception occurs for regular monitoring of asthma symp-
toms and pulmonary function during pregnancy and for
early recognition and prompt treatment of exacerbations
[47, 48]. This plan should include a review of the proper
use of medications, including the proper technique for
using inhalers; education about self-monitoring and self-
management at home; and speciﬁc instructions about when
to contact a health professional for additional care.
The National Asthma Education and Prevention Program
Working Group outlines a step-wise approach for managing
asthma during pregnancy in its report Managing Asthma
During Pregnancy: Recommendations for Pharmaceutical
Treatment—Update 2004. This report was developed after
a systematic review of the current evidence from safety
studies of asthma medications during pregnancy [46]. The
approach is centered on the use of beta2-agonoists and
corticosteroids, by inhalation when possible to minimize
systemic absorption. The dose, frequency, and number of
medications are decreased when possible but increased as
needed, and pulmonary function is measured regularly (e.g.,
by monthly spirometry testing) during pregnancy. The ap-
proachalsoemphasizestheneedforatreatmentplantailored
to each patient’s needs and circumstances, the frequency
and severity of her symptoms, and her individual response
to treatment. Regardless of the speciﬁcs, the beneﬁts and
risks of asthma treatment and of uncontrolled asthma during
pregnancy for both the mother and fetus should be discussed
SpringerS134 Matern Child Health J (2006) 10:S129–S135
during preconception planning so that a fully informed plan
for asthma management can be agreed upon.
Additional measures can be instituted preconceptionally
to minimize the severity or frequency of asthma symptoms
during pregnancy, and thus decrease reliance on, and fetal
exposure to, medications. Identifying, reducing, or elimi-
nating exposure to allergens such as animal dander, house-
dust mites, cockroaches, pollen, and indoor mold; to irri-
tants such as perfumes, sprays, and cleaning agents; and to
smoke, including primary and secondhand tobacco smoke,
wood burning stoves, or ﬁreplaces, may decrease asthma
symptoms. Preconception counseling also provides an op-
portunity to discuss the use of over-the-counter medications
for symptoms such as rhinitis, congestion, and esophageal
reﬂux that are often associated with asthma. While over-
the-counter medications can be purchased without a pre-
scription, they contain pharmacologically active ingredients
that may affect the fetus. For example, studies have sug-
gested that use of pseudoephedrine or aspirin in the ﬁrst
trimester may increase the risk of gastroschisis, a rare ab-
dominal wall defect [49–51]. It has been theorized that gas-
troschisis could result from vascular disruption. Both aspirin
and pseudoephedrine can have vasoactive effects, although
the causal pathway has not been established for either drug,
and the absolute risk of their use is very small. Most over-
the-counter medications have not been adequately studied in
pregnancy.
Conclusion
Although it is always better to avoid unnecessary medical
treatment during pregnancy, some women with chronic con-
ditions may not be able to become pregnant without ap-
propriate therapy. In many other cases, proper treatment of a
chronicconditionduringpregnancymaybesaferforboththe
womanandherbabythanstoppingthistreatment.Itisimpor-
tantthatwomenwhoareplanningapregnancytalkwiththeir
health care provider before beginning a new medication or
making changes in current medications for the management
of acute or chronic conditions. Continuous communication
between a pregnant woman and her health care providers,
careful preconceptional planning, effective management of
conditions prior to pregnancy, and close medical supervision
during pregnancy can help assure the best possible outcome
for every woman and baby.
New information about the effects of medication use and
theoptimalmanagementofmaternalconditionsduringpreg-
nancy continually becomes available. The following are reg-
ularly updated sources of such information and advice:
– The Organization of Teratology Information Specialists
(OTIS) provides medical consultation, usually by phone,
to individuals and health care providers about the repro-
ductive risks of prenatal exposures.
Phone: 866-626-6847
Website: http://otispregnancy.org
– REPROTOX r  isaninformationsourceforlaboratorysci-
entists, practicing physicians, and government agencies
that contains commentaries on the effects of chemicals
and physical agents on human pregnancy, reproduction,
and development.
Website: www.reprotox.org
– The Teratogen Information System (TERIS) is a com-
puterized database of summaries of individual agents de-
signed to assist health care professionals in assessing the
risks of exposures in pregnant women. Each summary is
based on a review of the published literature and includes
a risk assessment derived by consensus of an advisory
board of authorities in clinical teratology.
Website: http://depts.washington.edu/∼terisweb/teris
Information about the results of premarketing studies of
individual medications, including animal reproductive stud-
ies and human clinical trials, is usually available from the
drug manufacturer.
A list of many of the existing postmarketing pregnancy
registries that seek to monitor exposure to speciﬁc med-
ications during pregnancy is maintained by the Ofﬁce of
Women’s Health, U.S. Food and Drug Administration at
www.fda.gov/womens/registries.
Additional information is available from the March of
Dimes at www.marchofdimes.com/pnhec/173 1453.asp.
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